Pharmacosmos Therapeutics INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$4.8Mgeneral payments (2019-2025)
$1,975research payments (2019-2025)
10,369clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2020 $245K
2021 $589K
2022 $763K
2023 $1.1M
2024 $1.4M
2025 $688K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Hematology & Oncology $1.9M
Nephrology (Internal Medicine) $663K
Medical Oncology $390K
Hematology (Internal Medicine) $248K
Anesthesiology $240K
Cardiovascular Disease $204K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Myles Wolf Chicago, IL Nephrology (Internal Medicine) $585,120.74
Aryeh Shander Englewood, NJ Anesthesiology $226,678.96
Steven Fein Miami, FL Hematology & Oncology $178,127.38
Suresh Ratnam Mcallen, TX Medical Oncology $159,408.95
Christopher Chen Tucson, AZ Hematology & Oncology $140,992.98
Joshua Strauss Springfield, NJ Hematology & Oncology $125,224.12
Hassan Kaleem Tulsa, OK Hematology & Oncology $106,906.51
Martin Dietrich Rockledge, FL Hematology & Oncology $103,991.14
Ralph Boccia Bethesda, MD Hematology & Oncology $102,198.43
Ilya Blokh Brooklyn, NY Hematology & Oncology $84,144.71

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.